Colforsin (Forskolin, HL 362)

Catalog No.S2449 Synonyms: Coleonol, Colforsin

For research use only.

Colforsin (Forskolin, HL 362, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

Colforsin (Forskolin, HL 362) Chemical Structure

CAS No. 66575-29-9

Selleck's Colforsin (Forskolin, HL 362) has been cited by 106 publications

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Colforsin (Forskolin, HL 362, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  MoDWRZBweHSxc3nzJGF{e2G7 MXe0NOKh|ryP MW[0POKhcA>? M2PWTmROW09? M{K5b4lv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= NF3OUVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 M4TnbmFxd3C2b4Ppd{BCe3OjeR?= MUK0NOKh|ryP Ml3iOFjDqGh? MWDEUXNQ NIruW|BqdmS3Y3XzJINp[W6pZYOgbY4hfGinIIDoc5NxcG:{eXzheIlwdiC|dHH0eZMhd2ZiUGCyRUB1[XKpZYTz NH;5WnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  NHjyfoVCeG:ydH;zbZMhSXO|YYm= NE\PXVY1OMLizszN NVW3TndrPDkEoHi= M2HSfmROW09? MV3pcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 M{LkUWFxd3C2b4Ppd{BCe3OjeR?= NFXqTYY1OMLizszN M{DhVFQ5yqCq Mkj4SG1UVw>? MXvpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  MVLGeY5kfGmxbjDBd5NigQ>? NXnyPZY5PDEEoN88US=> MYS3JIQ> MU\EUXNQ M4e0dZJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= M17BT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
SW480 M3K5U2Z2dmO2aX;uJGF{e2G7 MljwOFDDqM7:TR?= NXq4TohFPyCm MULEUXNQ NH7odnhz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDWOFDDqM7:TR?= NE\WW5IxNTd{IHi= MXXEUXNQ MVvpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NETHZ4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 NX\TcGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[0NOKh|ryP M{HZcVAuPzJiaB?= NYPL[2p3TE2VTx?= NVH5[IZZcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  M1[yfGZ2dmO2aX;uJGF{e2G7 Mkn2OFDDqM7:TR?= NEKwSnM1QMLiaB?= M1TPO2ROW09? NHuzc2Vi[3SrdnH0[ZMhWFB{QR?= MljvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 M1vSTWZ2dmO2aX;uJGF{e2G7 NVLI[odlPDEEoN88US=> MX60POKhcA>? MXvEUXNQ NEnUdGNi[3SrdnH0[ZMhWFB{QR?= MoTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
C6 M2rnPWZ2dmO2aX;uJGF{e2G7 M3rIVVExKM7:TdMg MmnMNlAhdWmw NGLWZmhqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> NUTnTZZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlk1OTdpPkK1NFY6PDF5PD;hQi=>
Huh-7 NVnvfZYyTnWwY4Tpc44hSXO|YYm= NEPsWFMxNTJyIN88US=> NEnwV5MzKGkEoB?= NYj2cWx6emW|dXz0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KGmwY4LlZZNmKGmwIHOtUZlkKGW6cILld5Nqd25iYYSgeIhmKHC{b4TlbY4h[W6mIH3SUmEhdGW4ZXzz Ml76QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEm4N|QoRjJ3MUC5PFM1RC:jPh?=
THP-1  NVXGcGVTTnWwY4Tpc44hSXO|YYm= NXTVR5V4OS9zMDFOwG0> NFLHd4gzyqCq MorzSG1UV8Li NUeyfnpFe3WycILld5NmeyCPQ2CtNUBxem:mdXP0bY9vyqB? NU\u[JNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVQ5QDJpPkK1NVU1QDh{PD;hQi=>
BeWo  MWjGeY5kfGmxbjDBd5NigQ>? NHmzRVIzOCEEtV2= Ml7nOFghcA>? NUTkNG42TE2VT9Mg MVnpcoR2[2W|IHPlcIwh\nW|aX;u M4D1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUi0OFc4Lz5{NUG4OFQ4PzxxYU6=
ventricular cardiomyocytes  M2T0VGZ2dmO2aX;uJGF{e2G7 NWLteIlmOC5yMT2xNEDPxE1? M4PWcIV3d2unczDhckBqdm:2cn;wbYMhemW|cH;ud4UhOTJywsGxOUUh[WKxdnWgZoF{[Wxid3n0bEBidiCHQ{WwxsBw\iB{LkKgxtVO MlnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEOxNVMoRjJ3MkCzNVE{RC:jPh?=
ventricular cardiomyocytes  Ml\OSpVv[3Srb36gRZN{[Xl? NV3OSXZWOC5yMT2xNEDPxE1? NF7QW2NqdmO{ZXHz[ZMhKGODTWCgZYNkfW23bHH0bY9v MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyM{GxN{c,OjV{MEOxNVM9N2F-
MIN6  MXHGeY5kfGmxbjDBd5NigQ>? NWmwbIRHOTBizszNxsA> MYSzJIg> NUftRpNLcW6lcnXhd4V{KER|IH3SUmEh\XiycnXzd4lwdg>? NH\BVoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0NVEzPCd-MkWyOFEyOjR:L3G+
L6 M2WxNmZ2dmO2aX;uJGF{e2G7 MX:0NEDDvU1? M376NVI1KGh? NF3mdHFqdmirYnn0d{BFVUhzLXnu[JVk\WRiQXv0JIFkfGm4YYTpc44> NGPXXIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0O|U2OCd-MkWyOFc2PTB:L3G+
HEK‐CFTR NYqxN|J{TnWwY4Tpc44hSXO|YYm= MX[y5qCUPTEEoN88US=> NH7KOnkxNTF{IH3pci=> MWPEUXNQyqB? NIDue2tqdmS3Y3XzJIEh\G:|ZfMAlIRmeGWwZHXueEBqd2SrZHWg[YZndHW6wrC= NIDkb5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|IxPyd-MkWyOlMzODd:L3G+
SK-N-SH MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2n0VFExKM7:TdMg NEnW[ZI1QCCq MUnlcohidmOnczDTT{1PNVOKIH7leZJw[myjc4TvcYEh[2WubDD2bYFjcWyrdIm= MkC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  NH2zeHVHfW6ldHnvckBCe3OjeR?= NFfzeVYyOCEQvF5CpC=> NYPGZ4NTOTBxM{CvOlAhdWmw MXHpcoNz\WG|ZYOgcIV3\Wy|IH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCjbnSgbY5lfWOnczDhZ4N2dXWuYYTpc44hd2ZicD5Otk1k[XSnbnnuJEh{\XJ4N{WpJIlvKCiyZYLpLY52[2ynYYKgdoVocW:wcx?= MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  NEHKT2pHfW6ldHnvckBCe3OjeR?= M1PDOlExKM7:TdMg NXz3W4hnOzBibXnu M1izT4lv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJO6zNWOjdHXubY4hMHOnck[3OUktKHBvR2PLN:6zKCi|ZYK5LUBidmRiY3;uZ49ucXSjboSgbIlocGW{IHzleoVteyCxZjDhZ5RqfmVuIIXudIhwe3Cqb4L5cIF1\WRuIN8yMYNifGWwaX6= NHXLUIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  M325OGZ2dmO2aX;uJGF{e2G7 MUWxNEDPxE4EoB?= MonaNlQhcA>? MYLpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gZ5lkdGmwIFSx NUDPZox7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
SK-N-AS  NWDJXZAyTnWwY4Tpc44hSXO|YYm= M{fkTFExKM7:TdMg NW\uVVM6OjRiaB?= NHvy[m1qdmO{ZXHz[ZMhfGinIHPBUXAhdGW4ZXzzxsA> M4LqVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[2NFY{Lz5{NUK2OlA3OzxxYU6=
SK-N-AS  MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmWyNVAh|ryPwrC= NGmxR3MzPC92ODDo NFHVNppmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh MonpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
granulosa cells MUPGeY5kfGmxbjDBd5NigQ>? MX6xNEDPxE1? NHLq[5YzPCCq M1nMRolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUGwOUc,OjV|M{mxNFU9N2F-
granulosa cells NUntPHVrTnWwY4Tpc44hSXO|YYm= MlX6NVAh|ryP M4TSSVI1KGh? NFi2WYZqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 M3jQZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
granulosa cells MoXhSpVv[3Srb36gRZN{[Xl? NHjoWJgyOCEQvF2= NWT0T5lJOTJxMkSgbC=> NU[xR|R4cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdoVxd3K2ZYKgZYN1cX[rdImg[o9zKHSqZTDsc45o\XO2IH\yZYdu\W62IDlijLI5PTRxK{G4VmdUOi6OVVOp M{PmW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
granulosa cells M{TYdGZ2dmO2aX;uJGF{e2G7 MnSyNVAh|ryP NFLRXIEyOi9{NDDo MUfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\sLiUlfTNuKhdVKQQR?= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUGwOUc,OjV|M{mxNFU9N2F-
BeWo  M1Sx[2Z2dmO2aX;uJGF{e2G7 NVfZN3F7OjEEoNM1US=> MXS0POKhcMLi M1zHd2ROW00EoB?= MXPkc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDHR20uOQ>? NXTZ[VJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlIzPjBpPkK1N|YzOjZyPD;hQi=>
BeWo  MnPKSpVv[3Srb36gRZN{[Xl? Mn72NlDDqML3TR?= MlfLOFjDqGkEoB?= MWfEUXNQyqB? NIL6bIdld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 M2myeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[yNlYxLz5{NUO2NlI3ODxxYU6=
BeWo  NHLNW5hHfW6ldHnvckBCe3OjeR?= MYOyNOKhyrWP M3rNXVQ5yqCqwrC= NX\iRnQ4TE2VT9Mg M{XaeYlv[3KnYYPld{B1cGViYnX0ZU1pS0dicnXs[YF{\Q>? MmjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NkKyOlAoRjJ3M{[yNlYxRC:jPh?=
EM1  NYT4eoh[TnWwY4Tpc44hSXO|YYm= MmPzNVXjiIsQvF2= MnfoOFghcA>? NYXYfHBqemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR|Iue2muZX7j[YQhTU1zIHPlcIx{yqB? M1HTUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e4OlYyLz5{NUO3PFY3OTxxYU6=
Primary bovine chondrocytes NVK1W|FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L4VVXPxE1? MWi0PEBp MkS5doV3\XK|ZYOgeIhmKGmwaHnibZRwenliZX\m[YN1KG:oIHPlcIVkd3irYjDvckBxem:uaX\ldoF1cW:wIHnuJIdzd3e2aDDwcIF1\SClaH;u[JJw[3m2ZYO= MmPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2ME[wNVYoRjJ3NEC2NFE3RC:jPh?=
RBMECs NGLJV2lHfW6ldHnvckBCe3OjeR?= M1LRSVXDqM7:TR?= M2nkWVEhcA>? NGDKSGZjdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs MXnGeY5kfGmxbjDBd5NigQ>? MXq1xsDPxE1? NEX4fZQyKGh? NHW2TodjdG:la4OgeIhmKEWPQWCtTWkucW6mdXPl[EBkcGGwZ3WgbY4hVUyFIIDoc5NxcG:{eXzheIlwdg>? MlTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs M13SUWZ2dmO2aX;uJGF{e2G7 NF\RTVc2yqEQvF2= NGHOZ4QyKGh? MVfy[ZZmenOnczD0bIUh[2ijbnfld{BqdiCcTz2xJIRqe3S{aXL1eIlwdiC|ZXXuJJdqfGhiRV3BVE1KUSC2cnXheI1mdnR? M{nKXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs MWTGeY5kfGmxbjDBd5NigQ>? MXm1xsDPxE1? M4\HXlEhcA>? M1nNWIlvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs M3fkUGZ2dmO2aX;uJGF{e2G7 NXvlTmJ3PcLizszN M{fEZlEhcA>? MUDwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs M1;rN2Z2dmO2aX;uJGF{e2G7 NVLOc3FlPcLizszN MniyNUBp M4PSepBz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? NUO0Z|BPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs Mnn3SpVv[3Srb36gRZN{[Xl? NF7mVoE2yqEQvF2= M3;DeFEhcA>? NUKxSmZQ[myxY3vzJJRp\SCjY4TpeoF1cW:wIH;mJHJpd0FxUl;DT{BqdmS3Y3XkJIJ6KEWPQWCtTWk> M{XnZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs Ml\mSpVv[3Srb36gRZN{[Xl? MXuwMlA2NzBwNT:1JO69VQ>? Ml\UNE4zPSCq MX\pcoNz\WG|ZYOgZ2FOWCClb37j[Y51emG2aX;u NGjXOos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
ThGCs  M1K0emZ2dmO2aX;uJGF{e2G7 MX[xNQKBks7:TR?= MVWzJIg> MUXpcohq[mm2czD0bIUh\W[oZXP0JI9nKEh{T{Kgc44hTUSQMjDtVm5C NHrLS5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzN|AzPyd-MkW0N|MxOjd:L3G+
ThGCs  M3HDTWZ2dmO2aX;uJGF{e2G7 NX7T[4prOTEkgJtOwG0> M3PLfFTjiIqq MoC0bY5kemWjc3XzJGNwS2x{LXnu[JVk\WRiRVTONuKh\2WwZTDlfJBz\XO|aX;u NXrPNlFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
ThGCs  NXPnUZVNTnWwY4Tpc44hSXO|YYm= MkfhNVDjiIsQvF2= MoO4OQKBkmh? MlvGZZVodWWwdIOgTGlHOUFibHX2[Yx{KHSqYYSge4Vz\SC|dHnteYxifGWmIHL5JGNwS2x{ NVLsbVI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
LNCaP  NVq5NZpqTnWwY4Tpc44hSXO|YYm= NWL0RotJOTEEoN88US=> M1mxe|EzKGkEoB?= MlrKSG1UVw>? M1HKOYlv\HWlZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBw\iCFUlXCNUBi[3Srdnn0fS=> M4rEWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUS4NFk6Lz5{NUW0PFA6QTxxYU6=
BeWo MXLGeY5kfGmxbjDBd5NigQ>? MlT5NlDDqML3TR?= Ml\EOFjDqGh? NXjPSpJ3TE2VTx?= MX;pcoNz\WG|ZYOgeIhmKGGmaHXzbY9vKG:oIGTIVE0yKG2xbn;jfZRmew>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4Nke0NEc,OjV3Nk[3OFA9N2F-
BeWo Mn7oSpVv[3Srb36gRZN{[Xl? MmDpNlDDqML3TR?= M320XFQ5yqCq MYnEUXNQ NXfQPZZ1cW6lcnXhd4V{KHSqZTDkbYZn\XKnboTpZZRqd25ib3[gRoVYdyClZXzsdy=> NYq3O|dRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlY4PDBpPkK1OVY3PzRyPD;hQi=>
OCI-Ly18  MmPWSpVv[3Srb36gRZN{[Xl? M3nReVQxyqEQvF2= Ml7vNeKhcMLi NXj1fHhJTE2VTx?= M2TTb4lv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z NXHiUHFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O|YzOjBpPkK1OVc3OjJyPD;hQi=>
OCI-Ly1  MoHjSpVv[3Srb36gRZN{[Xl? M1TSXFQxyqEQvF2= NVXBfndpOcLiaNMg NHnGe|VFVVOR NYfnbHJScW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkKyNEc,OjV3N{[yNlA9N2F-
3T3-L1 NFXNTpBHfW6ldHnvckBCe3OjeR?= MnrxNk42NzVizszN M2LT[|I1KGkEoB?= M1;GNJNq\26rZnnjZY51dHliZHXjdoVie2W|IFHUS2wheHKxdHXpckBmgHC{ZYPzbY9vKGG2IHHscEBld3OnczD0[ZN1\WR? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEW5O{c,OjV3OUC1PVc9N2F-
HEK293  M3i2Z2Z2dmO2aX;uJGF{e2G7 M{XQNFXjiIoEtV2= NHr3RVE{OCCvaX6= NU\SNox{cW6lcnXhd4V{KGODTWCgcIV3\Wy| NG\wboQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NVkxQCd-MkW1PVE6ODh:L3G+
hADSCs M37yW2Z2dmO2aX;uJGF{e2G7 MWO15qCKyrWP M4PQe|MxKG2rbh?= MXPpcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> M3i0[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUmxPVA5Lz5{NUW5NVkxQDxxYU6=
SH-SY5Y  MU\GeY5kfGmxbjDBd5NigQ>? MoPKNVDDqM7:TR?= MYCxxsBpyqB? M{LPb4lv[3KnYYPld{BCT0NzIH3SUmEhdGW4ZXy= NX3UPYc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
SH-SY5Y  NHiz[4NHfW6ldHnvckBCe3OjeR?= NU\rXJdCOTEEoN88US=> M37ZS|HDqGkEoB?= MYnpcoNz\WG|ZYOgUHVEKGGldHn2bZR6 NVrsTYVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
UACC-647  NHXiTG1HfW6ldHnvckBCe3OjeR?= M{n3N|ExyqEQvF2= NH60W|QyPSCvaX6= MX7EUXNQ M4DrNolv[3KnYYPld{BmTUZ{IIDoc5NxcG:{eXzheIlwdiCuZY\lcJPDqA>? M1nvbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNFI2Lz5{NUewN|AzPTxxYU6=
UACC-647  MULGeY5kfGmxbjDBd5NigQ>? MmfWNVDDqM7:TR?= MXmxOUBucW5? M3HENmROW09? NYXqeGhDcW6qaXLpeJMhTVKNIIDoc5NxcG:{eXzheIlwdg>? NGriTWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN|AzPSd-MkW3NFMxOjV:L3G+
UACC-647  MVrGeY5kfGmxbjDBd5NigQ>? NUjVN5ZYTE2VTx?= M1\De4xm[WS|IITvJIEhemm|ZTDpckBkSU2SIHzleoVteyBqRVO1NOKhRcLiMkCuN|nDqM7:TTm= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyM{CyOUc,OjV5MEOwNlU9N2F-
SC M{PWOmZ2dmO2aX;uJGF{e2G7 MXywMlUh|ryP NEfV[Go4OiCq M1XzTYlv[3KnYYPld{Bjd3SqIFvyc5guOjBiYX7kJG8yKGW6cILld5Nqd25iaX6gZZhwdi2{ZXzheIVlKFOFczDieZQhd26ueTDLdo95NTJywrC= NWj2PFlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFU5PzRpPkK1O|A2QDd2PD;hQi=>
SC MWrGeY5kfGmxbjDBd5NigQ>? M1zjXVAvPSEQvF2= MYGyOEBp Mn32cYlucWOtczD0bIUh\W[oZXP0JI9nKGODTWCgZY5idG:pczDvckBQOSCjbnSgUWJRKGW6cILld5Nqd25? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyNUi3OEc,OjV5MEW4O|Q9N2F-
oocytes M{XQXWZ2dmO2aX;uJGF{e2G7 NXfBXXZDPSEQvF2= NXy5PJdYOjRiaB?= NHjtZ5BifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?= M{LuSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{C3PFU1Lz5{NUewO|g2PDxxYU6=
BeWo NV31Tm9TTnWwY4Tpc44hSXO|YYm= M{TrclEx6oDMzszNxsA> NY\CUHRjPzJiaB?= M2rvdWROW09? NH2ycXNu\WSrYYTld{BD\VexIHPlcIwh\GmoZnXy[Y51cWG2aX;u NXi0V4RWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NVM1OjVpPkK1O|E{PDJ3PD;hQi=>
GH3 MoT2SpVv[3Srb36gRZN{[Xl? NUDuPXBEOcLizszN NFi0c|I3NWh? NXToU4p4cW6mdXPld{BRWkxiYX7kJGJu[WxzLDDieZQhdm:2IFPsc4NsNCCvUl7BJIV5eHKnc4Ppc44> NVvQRndsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlcxOThpPkK1O|I4ODF6PD;hQi=>
GH3 M3fG[2Z2dmO2aX;uJGF{e2G7 MmHwNeKh|ryP M{fvfVYucA>? MY\heJRmdnWjdHXzJJRp\SClb4Ly[YxifGmxbjDi[ZR4\WWwIGDSUEBidmRiQn3hcFEh\XiycnXzd4lwdg>? M4ToUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3NFE5Lz5{NUeyO|AyQDxxYU6=
PC12 NIHrUZdHfW6ldHnvckBCe3OjeR?= M4DaUFI2yqEQvF2= NFvpSWk1QCCq M3i3S4FkfGm4YYTld{BkSU2S MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUOwOUc,OjV5NkmzNFU9N2F-
BAECs NH3JWGVHfW6ldHnvckBCe3OjeR?= M122R|I2KM7:TR?= MYCyOEBp MVnlcohidmOnczD0bIUh[WO2aY\heIlwdiCxZjDQVGFT|rFiYomgOUDPxE1icnXzeoVz[XS{b3ysJHQ1UFNuIH;yJFQuWEGS NUTNO5ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVg5OjZpPkK1O|k5QDJ4PD;hQi=>
GLUTag  NILaRZZHfW6ldHnvckBCe3OjeR?= NUTkN3NNOTEkgJpCuW0> NH3YZnY1KGh? NIrMdmhqdmO{ZXHz[ZMhfGinIIDDVmVDKGyndnXsd{B4cXSqIITo[UBKSk2[ M3PHV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
GLUTag  MXzGeY5kfGmxbjDBd5NigQ>? NFfpcHcyOOLCidM1US=> M3riTFAwOi92IHi= MWHzeIlufWyjdHXzJGdNWC1zIIPlZ5JmfGmxbjDjc5Rz\WG2ZXSge4l1cCCLQl3Y M33FNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
PBMC NFjnfmFHfW6ldHnvckBCe3OjeR?= MVW1NOKh|ryP MWOyOOKhcMLi MWPpcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG NWq5UJdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlYxPzlpPkK1PFY3ODd7PD;hQi=>
H295R  NGPoSJFHfW6ldHnvckBCe3OjeR?= M4r3VVExyqEQvF2= M1;jW|Q5yqCq NH\1UVVqdmO{ZXHz[ZMhe3Sncn;p[EBu\XSjYn;sbZRmeyCrbjD0bIUh[W6mcn;n[Y4tKG2rbnXyZYxwNSCjbnSg[4x2[2:lb4L0bYNwcWRicHH0bJdigXN? NETNNIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2PVU2Pid-MkW4Olk2PTZ:L3G+
3T3-L1 preadipocytes M3P0fmZ2dmO2aX;uJGF{e2G7 NHPiRZcyOCEQvF5CpC=> MknHNVIhcA>? Ml7NbY5lfWOnczDDVmVDKHCqb4PwbI9zgWyjdHnvckBidmRiQz;FRnDPuiCneIDy[ZN{cW:w NVPYZoNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NlgxPThpPkK1PVI5ODV6PD;hQi=>
PCCL3 NICwR4dHfW6ldHnvckBCe3OjeR?= M4TOT|ExKML3TR?= NEfrVY8zPCCq NWLXRZdi\W6qYX7j[ZMhTHWReEKgdJJwdW:2ZYKgeJJidnOlcnnweIlwdiCjY4Tpeol1gcLi4pEL M{H3TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wPVU3Lz5{NUm2NFk2PjxxYU6=
SCG NV\4XI54TnWwY4Tpc44hSXO|YYm= MUKxNFAh|ryPwrC= M4nmVWROW09? MXny[YR2[2W|IITo[UBmgGOrdHHibYxqfHlib3[gV2NIKG6ndYLvcpM> MlTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkKxN|IoRjJ3OU[yNVMzRC:jPh?=
HEK-293 MkX2SpVv[3Srb36gRZN{[Xl? MmfEN|Uh|ryPwrC= MVzEUXNQ NEDWSm5qdmS3Y3XzJIEh[2:wc4DpZ5VwfXNi4pEcbY5i[3SrdnH0bY9v6oDfIH;mJJRp\SCNdkKuNUBkfXK{ZX70 M1u3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[yNVMzLz5{NUm2NlE{OjxxYU6=
SCG MoHsSpVv[3Srb36gRZN{[Xl? NVnub3o4OjBizszNxsA> NHLi[ZRFVVOR M{[2R5JmfmW{c3nicJkhe3WycILld5NmeyCLS2[ge4l1cCCjIFnDOVAhd2ZiMkSuOEDPxE1? M1LKZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[yNVMzLz5{NUm2NlE{OjxxYU6=
PC-3 M{DXcmNmdGxiVnnhZoltcXS7IFHzd4F6 MoXUOFAhyrWP M1HTXFI1NzR6L{eyJIg> MX3EUXNQ NX;1TFdx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm= MmPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkO4N|YoRjJ4MEKzPFM3RC:jPh?=
PC-3 M3K3RmZ2dmO2aX;uJGF{e2G7 MXW0NEDDvU1? MoPQNkBp MXnEUXNQ MlHjcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w NXfrcFU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlM5OzZpPkK2NFI{QDN4PD;hQi=>
SH-SY5Y MnK0SpVv[3Srb36gRZN{[Xl? NXXFe4l7OzBizszN NFrSbVY{OCCvaX6= M2HNXGROW09? NFrFN2h{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUh[WO2aY\heIlwdiCxZjDQT2E> NEDTfJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyOVE{Pyd-Mk[wNlUyOzd:L3G+
EndoC-βH1 M2L6dWZ2dmO2aX;uJGF{e2G7 MWq1xsDPxE1? MXWxJIg> M{fIUYxm[WS|IITvJIEhe3S{b37nJINCVVBiaX7jdoVie2V? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{OEW2Nkc,OjZyMki1OlI9N2F-
EndoC-βH1 M3;GOmZ2dmO2aX;uJGF{e2G7 MX:1xsDPxE1? NHnWfWYyKGh? NG\3NXpxd3SnboTpZZRmeyCpbIXjc5NmNWmwZIXj[YQhcW6|dXzpckB{\WO{ZYTpc44hcW5idHjlJJBz\XOnbnPlJI9nKGeudXPvd4U> MoL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMki1OlIoRjJ4MEK4OVYzRC:jPh?=
RBMECs NGjtU|BHfW6ldHnvckBCe3OjeR?= NIPiVHY2yqEQvF2= M1vLUVEhcA>? M{\u[4lvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh MlTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNES2OlMoRjJ4MES0OlY{RC:jPh?=
AML-12  M1PiSGZ2dmO2aX;uJGF{e2G7 NHj3e5gzOCEQvF2= MVyzJIg> M4LHdYlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? Mn:0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  MX3GeY5kfGmxbjDBd5NigQ>? MYCyNEDPxE1? NVu0eZdxOyCq NGHjSpJ2eC2{ZXf1cIF1\XQEoGDnZ|FiNMLiUHXwZ4stKGGwZNMgS|Zx[8LibWLORUBt\X[nbIO= MnjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEi5PFUoRjJ4MES4PVg2RC:jPh?=
AML-12  M2\TeGZ2dmO2aX;uJGF{e2G7 Ml2zNlAh|ryP MV[xMVghcA>? MYHpcoNz\WG|ZYOg[4x2[2:|ZTDwdo9lfWO2aX;u NHnxS|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PFk5PSd-Mk[wOFg6QDV:L3G+
AML-12  M3vMWWZ2dmO2aX;uJGF{e2G7 MkWxNlAh|ryP NWrFdHJjOyCq NXfSSItkfXC{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNiYYSgWIhzNTRzMTDhcoQhW2W{LUS5Ny=> M{fCd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES4PVg2Lz5{NkC0PFk5PTxxYU6=
Caco-2  MYDGeY5kfGmxbjDBd5NigQ>? M1nKb|AvOS9zL{GwJO69VQ>? MnvSNlQhcA>? NXGwToZNcW6lcnXhd4V{KE2UUEKgdJJwfGWrbjDs[ZZmdA>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OUGwNkc,OjZyNEmxNFI9N2F-
Caco-2  M4WxS2Z2dmO2aX;uJGF{e2G7 NGe4SVYxNjFxMT:xNEDPxE1? M{LFbFIxyqCvaX6= MY\pcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWucx?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OUGwNkc,OjZyNEmxNFI9N2F-
bovine oocytes NGjEb5lHfW6ldHnvckBCe3OjeR?= Ml3SNVAxyqEQvF2= NXXXVm12OTMEoHi= NHXUT3FqdmirYnn0d{B1cGViZX\m[YN1KG:oIF7QVGEh[W6mL3;yJG5RWENidH:gd5RqdXWuYYTlJJJme3WvcITpc44hd2ZibXXpc5Nqew>? MorEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUG2NVEoRjJ4MEWxOlEyRC:jPh?=
BeWo  NInzXGxHfW6ldHnvckBCe3OjeR?= MV:yOgKBkc7:TR?= MVGyOE81QC95MjDo MmfncIVi\HNidH:gZY4hcW6lcnXhd4UhcW5idHjlJIV5eHKnc4Ppc44hd2Zib4To[ZIh\nW|aX;uJI1iemuncoO= MnTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUO1OFkoRjJ4MEWzOVQ6RC:jPh?=
Spinal cords  MmCxSpVv[3Srb36gRZN{[Xl? MkPrNeKh|ryP NVPYUJNIOzBibXnu MUjzeIlufWyjdHXzJINCVVBibHX2[Yx{ NEnGbZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOlkzPid-Mk[xNlY6OjZ:L3G+
MDCK  Mn24SpVv[3Srb36gRZN{[Xl? MkTWNVAhyrWP MnPNNlQhcA>? MXfEUXNQ NIrkSnFqdmirYnn0d{B1cGViaX7jdoVie2WmIHX4dJJme3Orb36gc4YhTk5iY3H1d4VlKGK7IGTHSk3PujF? NWe4Xm1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
MDCK  M1nBO2Z2dmO2aX;uJGF{e2G7 NI\2bpgyOCEEtV2= MYmyOEBp M4nPcGROW09? MXj1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBVT0ZvzsKxJIFv\CCFVFfGxsA> MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEKzOVIoRjJ4MkCyN|UzRC:jPh?=
RPMI 8226 MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXTz[IV{OC1zMECg{txO M161NFcz6oDLaB?= NWrmXHZLcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> NG\vdJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
H929 M2H2cmNmdGxiVnnhZoltcXS7IFHzd4F6 MXOwMVExOCEQvF2= NFLoUWY4OuLCiXi= M2DOOYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NYLVRoRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zNFY3OjRpPkK2N|A3PjJ2PD;hQi=>
U266 NWjoOGI3S2WubDDWbYFjcWyrdImgRZN{[Xl? NYDyVFVCOC1zMECg{txO MVy3NwKBkWh? MoPhbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NHK1dno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
OPM-2 MlvPR4VtdCCYaXHibYxqfHliQYPzZZk> MnKwNE0yODBizszN NH;6NYk4OuLCiXi= M3ry[Ilv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NIrmOnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
INA-6 M2\yWGNmdGxiVnnhZoltcXS7IFHzd4F6 MorhNE0yODBizszN MlXuO|LjiImq MkHtbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NH:0foo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
RBMECs  NWXsZml4TnWwY4Tpc44hSXO|YYm= MkCzOeKh|ryP Mm\zNeKhcA>? NEf1[4pjdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? M1zkSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{W4NFM6Lz5{NkO1PFA{QTxxYU6=
Mo-DCs NXjReZBnTnWwY4Tpc44hSXO|YYm= MV61NEDPxE1? MlPhNlTjiImq NFiwcnFxem:vb4Tld{BKVC1{MzDwdo9lfWO2aX;uJIlvKHSqZTDzeZBmem6jdHHueEBw\iC8eX3vd4FvKHO2aX31cIF1\WRiTX:tSGN{yqB? NFL6[oI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSxNlk1QCd-Mk[0NVI6PDh:L3G+
HEK293 MkTRSpVv[3Srb36gRZN{[Xl? NWj5Z2JIOTBizszN MkG0OkBp NV:5XJpucW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR|NUS5PEc,OjZ2M{W0PVg9N2F-
ASK NXy0NXNDTnWwY4Tpc44h[XO|YYm= NWLsT4dkOSCqch?= M3i2O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEm2OFEoRjJ6NEm2OFE9N2F-
Vero E6 M3fKSWFvfGm4aYLhcEBie3OjeR?= M37jd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[zOVM6Lz5zN{[2N|U{QTxxYU6=
epithelial cells NGfHdohHfW6ldHnvckBie3OjeR?= MY[xJJVO NXPZdGZ3PCxiNjygZY5lKDhiZHH5dy=> NEHmVlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
HepG2 (DPX-2) Mk\KSpVv[3Srb36gZZN{[Xl? NVrhO4JXOjRiaILz MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HepG2 M2fBfGZ2dmO2aX;uJIF{e2G7 MmroNlQhcHK| MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl4NkC0N{c,OjB7Nk[wOFM9N2F-
HepG2 (DPX-2) NEjGS4FHfW6ldHnvckBie3OjeR?= M{XWclI1KGi{cx?= MlroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HEK293T MXnGeY5kfGmxbjDhd5NigQ>? MkfUNVAhfU1? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN6N{OyOUc,OjR|OEezNlU9N2F-
HEK293 NUPyNmtOTnWwY4Tpc44h[XO|YYm= NWPyXVlmOTBidV2= NGP4fnMyPiCqcoO= NYLr[5FbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0N|U2OTJpPkK2OFM2PTF{PD;hQi=>
MCF7 NEGxdWVEgXSxdH;4bYNqfHliYYPzZZk> MWG0PEBpenN? NVjVXmFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N|g3QTJpPkK4PFM5Pjl{PD;hQi=>
HEK293 MkPPSpVv[3Srb36gZZN{[Xl? NHzFb5k{OCCvaX7z MmHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xO|YoRjNyMEC2NVc3RC:jPh?=
Assay
Methods Test Index PMID
Western blot cleaved caspase-3 / caspase-3 ; cleaved caspase-9 / caspase-9 ; β-catenin ; c-myc / Cyclin D1 ; pS6K1 / S6K1 / pCREB / CREB ; p-JNK / JNK / P-p38 / p38 30863177 31112131 20070884
Immunofluorescence 5hmC ; Fe(II) ; CYP17A1 / CYP21A2 29239726 25334044
Growth inhibition assay Cell viability 30863177

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 82 mg/mL
(199.75 mM)
Water Insoluble
Ethanol ''37 mg/mL

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT02807415 Completed Drug: Lumacaftor plus Ivacaftor Cystic Fibrosis Hannover Medical School|Heidelberg University|University of Giessen June 1 2016 --
NCT02586883 Completed Other: bronchial ddp test Idiopathic Dilation of the Bronchi Assistance Publique - Hôpitaux de Paris March 29 2016 Not Applicable
NCT03652090 Completed Procedure: cell sampling Cystic Fibrosis Institut National de la Santé Et de la Recherche Médicale France|ABCF2 September 1 2010 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362) supplier | purchase Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362) cost | Colforsin (Forskolin, HL 362) manufacturer | order Colforsin (Forskolin, HL 362) | Colforsin (Forskolin, HL 362) distributor